Inhaled and Intravenous Application of a Stimulator of the Soluble Guanylate Cyclase (BAY 41-8543) Reduces Pulmonary Vascular Resistance in a Model of Septic Shock

BMC Pharmacology
doi 10.1186/1471-2210-11-s1-p41
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

BAY 63–2521, an Oral Soluble Guanylate Cyclase Stimulator, Has a Favourable Safety Profile and Decreases Peripheral Vascular Resistance in Healthy Male Volunteers

BMC Pharmacology
2007English

Effects of Age and Sex on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Pulmonary Circulation
PulmonaryRespiratory Medicine
2016English

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats

PLoS ONE
Multidisciplinary
2012English

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats

BMC Pharmacology
2011English

EXPRESS: First-In-Child Use of the Oral Soluble Guanylate Cyclase Stimulator Riociguat in Pulmonary Arterial Hypertension

Pulmonary Circulation
PulmonaryRespiratory Medicine
2017English

The Effects of the Soluble Guanylate Cyclase Stimulator Riociguat on Memory Performance in Healthy Volunteers With a Biperiden-Induced Memory Impairment

Psychopharmacology
Pharmacology
2018English

Molecular Steps in Soluble Guanylate Cyclase Activation

BMC Pharmacology
2005English

A Nitric Oxide/Cysteine Interaction Mediates the Activation of Soluble Guanylate Cyclase

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Soluble Guanylate Cyclase Stimulators and Phosphodiesterase-5 Inhibitors in Therapy of Some Groups of Pulmonary Hypertension

Pulmonologiya
PulmonaryRespiratory Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy